Vascular effect of bevacizumab: is it too early to draw conclusions?
J Hypertens
.
2020 Feb;38(2):201-202.
doi: 10.1097/HJH.0000000000002254.
Authors
Stefano Masi
1
,
Javier Rosada
2
,
Agostino Virdis
1
Affiliations
1
Department of Clinical and Experimental Medicine, University of Pisa.
2
Fourth Unit of Internal Medicine, University Hospital of Pisa, Pisa, Italy.
PMID:
31913945
DOI:
10.1097/HJH.0000000000002254
No abstract available
Publication types
Editorial
Comment
MeSH terms
Angiogenesis Inhibitors
Arteries
Bevacizumab
Forearm*
Vascular Endothelial Growth Factor A*
Substances
Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Bevacizumab